^
    Back
    Association details:
    Biomarker:NRAS wild-type
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Monitoring RAS Phenotypic Changes Based on ctDNA to Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer

    Excerpt:
    ...Histological RAS gene detection KRAS, NRAS is wild type; 7. ...
    Trial ID:
    ChiCTR1900026962
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Multicenter prospective single-arm study investigating the efficacy and safety of second-line cetuximab plus chemotherapy treatment in initially RAS-mt mCRC patients who converted to RAS-wt at the time of first progression Studio di fase II a singolo braccio di terapia di II linea con cetuximab e chemioterapia in pazienti con carcinoma colorettale metastatico KRAS e NRAS mutato alla diagnosi con assenza di mutazioni di KRAS/NRAS su plasma alla progressione da prima linea

    Excerpt:
    ...- KRAS/NRAS-wt status, tested on ctDNA, at the time of progression after first line treatment- Life expectancy of at least 3 months; • Diagnosi istologica di adenocarcinoma del colon-retto• KRAS/NRAS mutato su biopsia tissutale (tumore primitivo /metastasi) al momento della diagnosi• Evidenza radiologica di progressione di malattia dopo prima linea con chemioterapia e bevacizumab• Malattia misurabile secondo criteri RECIST (RECIST criteria, vers.1.1); • Uomo o donna, età > 18 anni • ECOG Performance Status = 2; • Adeguata funzionalità ematologica, epatica e renale valutata entro 14 giorni dall'inizio del trattamento in studio Adequate bone marrow function (without hematopoietic growth factor or transfusion support within 14 days prior to study enrollment), including:a. ...
    Trial ID:
    2019-001328-36
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

    Excerpt:
    ...- c-MET positive (defined by c-MET IHC intensity score +2 in ≥ 50% of tumor cells and MET gene copy number ≥ 5 by FISH or IHC intensity score +3 in ≥ 50% of tumor cells) and K/NRAS WT status for mCRC patients only...
    Trial ID:
    NCT02205398
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients

    Excerpt:
    ...- KRAS, NRAS, BRAF wild-type;...
    Trial ID:
    CIFRA
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy

    Excerpt:
    ...An ARMS-PCR proven KRAS, NRAS, PI3KCA and BRAF wild type; 3....
    Trial ID:
    NCT04923620
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

    Excerpt:
    ...- Proof of a RAS wild-type tumour (KRAS and NRAS exons 2-4) in a tumour biopsy (metastasis) within 4 weeks before randomisation...
    Trial ID:
    FIRE-4
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

    Excerpt:
    ...KRAS and NRAS wild-type genes after analysis of mutation status from the primary tumour or metastasis 3....
    Trial ID:
    TIME-PRODIGE 28 UNICANCER
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer

    Excerpt:
    ...Patients with wild-type KRAS,NRAS and BRAF V600E metastatic colorectal adenocarcinoma confirmed by histology and genetic testing....
    Trial ID:
    NCT04718038
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer

    Excerpt:
    ...- The colorectal primary tumor or metastatic tumor must be determined to be KRAS and NRAS wild-type....
    Trial ID:
    FOCULM
    Less C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    Right vs left-sided RAS wild-type metastatic colorectal cancer treated with EGFR inhibitors: prognostic differences

    Published date:
    07/01/2019
    Excerpt:
    A retrospective study of a total of 44 patients with metastatic and KRAS/NRAS wt status CRC, treated with cetuximab or panitumumab was performed...In patients with mCRC RAS wt treated with EGFR inhibitors, regardless of the line of treatment, the right-side location was associated with poor survival
    DOI:
    https://doi.org/10.1093/annonc/mdz155.193